Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SHE:300937)
China · Delayed Price · Currency is CNY 25.22
+0.07 (0.28%)
At close: Aug 27, 2026
SHE:300937 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,406 | 3,261 | 2,394 | 3,009 | 2,761 | 4,358 | |
Market Cap Growth | -15.89% | 36.25% | -20.45% | 8.97% | -36.64% | - |
Enterprise Value | 2,165 | 3,264 | 2,406 | 2,978 | 2,728 | 4,281 |
Last Close Price | 25.15 | 34.09 | 24.93 | 31.03 | 28.29 | 44.66 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 181.33 | 50.54 | 65.71 | 680.87 |
PS Ratio | 0.54 | 0.73 | 0.55 | 0.68 | 0.70 | 1.28 |
PB Ratio | 3.06 | 4.08 | 2.86 | 3.52 | 3.37 | 5.53 |
P/TBV Ratio | 3.17 | 4.27 | 3.08 | 3.80 | 3.70 | 5.98 |
P/FCF Ratio | - | - | 26.01 | - | 20.55 | - |
P/OCF Ratio | 2010.32 | - | 19.24 | - | 18.09 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 0.48 | 0.73 | 0.55 | 0.67 | 0.69 | 1.26 |
EV/EBITDA Ratio | 47.65 | 67.91 | 51.90 | 32.01 | 35.22 | 320.29 |
EV/EBIT Ratio | 89.51 | 116.83 | 94.71 | 40.26 | 46.88 | 117838.91 |
EV/FCF Ratio | - | - | 26.15 | - | 20.31 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.38 | 0.42 | 0.47 | 0.39 | 0.30 | 0.17 |
Debt / EBITDA Ratio | 6.60 | 6.11 | 6.83 | 3.35 | 2.97 | 7.81 |
Debt / FCF Ratio | - | - | 4.23 | - | 1.81 | - |
Net Debt / Equity Ratio | -0.28 | -0.10 | 0.00 | -0.06 | -0.27 | -0.03 |
Net Debt / EBITDA Ratio | -4.97 | -1.74 | -0.08 | -0.54 | -2.86 | -1.79 |
Net Debt / FCF Ratio | 27.94 | 4.03 | -0.04 | 0.33 | -1.65 | 0.13 |
Asset Turnover | 2.43 | 2.60 | 2.59 | 2.70 | 2.86 | 3.36 |
Inventory Turnover | 8.52 | 7.28 | 7.40 | 8.08 | 8.01 | 7.99 |
Quick Ratio | 0.87 | 0.74 | 0.84 | 0.80 | 0.83 | 0.63 |
Current Ratio | 1.44 | 1.55 | 1.64 | 1.72 | 1.68 | 2.20 |
Return on Equity (ROE) | -2.65% | -2.01% | 1.30% | 6.78% | 4.50% | 1.03% |
Return on Assets (ROA) | 0.82% | 1.02% | 0.94% | 2.82% | 2.62% | 0.00% |
Return on Invested Capital (ROIC) | 3.82% | -8.28% | 2.85% | 8.56% | 6.88% | 0.01% |
Return on Capital Employed (ROCE) | 3.00% | 3.40% | 2.90% | 8.30% | 6.90% | 0.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.61% | -0.39% | 0.55% | 1.98% | 1.52% | 0.15% |
FCF Yield | -0.32% | -0.64% | 3.84% | -5.01% | 4.87% | -4.26% |
Dividend Yield | 0.40% | - | 0.40% | 0.71% | 0.71% | - |
Payout Ratio | - | - | 229.17% | 40.51% | 12.63% | 322.93% |
Buyback Yield / Dilution | -21.87% | -23.24% | 19.13% | -0.56% | -4.44% | -26.94% |
Total Shareholder Return | -21.47% | -23.24% | 19.53% | 0.15% | -3.73% | -26.94% |